Haematological MalignancyPhase 2/3RATIONALISENCT05678621
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
A Phase 2/3 study testing trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin and Immunoglobulins in people with Haematological Malignancy and Hypogammaglobulinemia, run by Monash University at 7 sites in Australia.
Trial summary
The aim of the study is to find out if patients with blood cancers receiving immunoglobulin (Ig) for the purpose of preventing infections can safety stop immunoglobulin after six months of therapy, and take oral antibiotics instead to prevent serious infections. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Haematological Malignancy, Hypogammaglobulinemia
- What is being tested?
- trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin and Immunoglobulins
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 7 sitesAustralia
- Study dates
- 30 Nov 2022to Apr 2027
- Phase
- Phase 2/3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged greater than or equal to 18 years of age
- Diagnosis of chronic lymphocytic leukaemia (CLL), multiple myeloma (MM) or non-Hodgkin lymphoma (NHL).
- Patients must be receiving Ig (IV or subcutaneous - SCIg) replacement for prevention of bacterial infections due to hypogammaglobulinaemia for longer than 6 consecutive months.
- Patient is eligible for trial of Ig cessation in the opinion of the treating clinician and local investigator.
- Life expectancy greater than 12 months.
- Able to give informed consent, and willing and able to comply with each of the treatment arms.
Who cannot join
- Prior or planned allogeneic haematopoietic stem cell transplantation.
- Major infection (Grade 3 or higher) in preceding 3 months, and/or current active infection requiring antimicrobial treatment.
- Already receiving daily antibiotic prophylaxis for the purpose of preventing bacterial infection (Note: patients may receive antiviral, antifungal and Pneumocystis jirovecii pneumonia (PJP) prophylaxis).
- Intolerance of all trial antibiotic options in either arm A or arm B.
- Communication, compliance or logistical issues that are likely to limit patient's ability to take prophylactic or emergency antibiotics, or to obtain urgent medical attention for symptoms of infection.
- Pregnant or breastfeeding.
Show all 10Show fewer
- Severe renal impairment (estimated or measured creatinine clearance of less than 30 mL/min).
- Previous splenectomy.
- Previous participation in this trial.
- Treating team deems enrolment in the study is not in the best interests of the patient.
Trial locations and contacts
7 sites in 1 country. Contact the study team or a site near you to ask about taking part.
7 sites in 1 country
Australia7 sites, 7 recruiting
- Recruiting
Monash Medical Centre
Clayton, Victoria, 3168
- Recruiting
Concord Hospital
Concord, New South Wales, 2139
- Not yet recruiting
Canberra Hospital
Garran, Australian Capital Territory, 2605
- Recruiting
Austin Hospital
Heidelberg, Victoria, 3084
- Recruiting
The Alfred Hospital
Melbourne, Victoria, 3004
- Recruiting
Sunshine Hospital
St Albans, Victoria, 3021
- Not yet recruiting
Royal North Shore
St Leonards, New South Wales, 2065
About this study
Official title: A Randomised Controlled Trial of Continuing Immunoglobulin Therapy, or Stopping With or Without Prophylactic Antibiotics, on Infection Rate in Patients With Acquired Hypogammaglobulinemia Secondary to Haematological Malignancies.
The aim of the study is to find out if patients with blood cancers receiving immunoglobulin (Ig) for the purpose of preventing infections can safety stop immunoglobulin after six months of therapy, and take oral antibiotics instead to prevent serious infections.
Patients may be eligible to join this study if they are aged 18 years or above, have an acquired hypogammaglobulinaemia secondary to a haematological malignancy, and have been receiving intravenous or subcutaneous Ig for longer than 6 consecutive months.
Read more
Participants will be randomised (allocated by chance) to one of three treatment groups, as follows:
- Stop immunoglobulin (IVIg or SCIg) and be given oral antibiotics to take every day (ARM A)
- Stop immunoglobulin (IVIg or SCIg) and be given oral antibiotics to keep at home to use as soon as symptoms of an infection develop (ARM B)
- Continue receiving immunoglobulin (IVIg or SCIg) - this is the usual care group (ARM C)
The duration of each treatment is for 12 months from study entry.
Participants will be asked to attend a screening/baseline visit so that their treating clinician can assess their eligibility for the trial and collect baseline data. If eligible for the trial, participants will then be randomly allocated to one of the three treatment groups.
Once randomised, active participation in the study will last for 13 months. During this period, participants will be asked to return to the hospital for a study visit every 3 months, with monthly telephone visits to check-in on your progress between each in-person visit. Participants will also be asked to complete a study diary, recording treatment compliance and signs/symptoms of infection experienced throughout the study period.
Types of assessments and data collected will include: Medical history, demographics, physical examination, blood tests, stool sample, quality of life questionnaires, information about your general health, hospitalisations, medications and procedures. In order to assess and compare the cost-effectiveness of the treatment groups, the study team will also request authorisation from participants to access their Medicare Benefits Schedule (MBS), Pharmaceutical Benefits Scheme (PBS), and Australian Immunisation Register (AIR) data.
- Conditions
- Haematological Malignancy, Hypogammaglobulinemia
- Being tested
- trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin, Immunoglobulins
- Keywords
- Myeloma, Lymphoma, Leukaemia, Blood cancer, Malignancy, Infection, Antibiotic, Anti-infective agent, Immunoglobulin
- Medical subject headings
- Hematologic Neoplasms, Agammaglobulinemia, Neoplasms, Plasma Cell, Lymphoma, Leukemia, Neoplasms, Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
trimethoprim-sulfamethoxazole (co-trimoxazole)Drug
Doxycycline is an alternative for participants with hypersensitivity to co-trimoxazole.
amoxycillin/clavulanic acid and ciprofloxacinDrug
clindamycin is an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.
ImmunoglobulinsDrug
Intravenous monthly immunoglobulin or subcutaneous weekly immunoglobulin
| Study group | Role | What they receive |
|---|---|---|
| ARM A: Stop immunoglobulin (Ig) and commence prophylactic oral antibiotics | Experimental | Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. Nb: Doxycycline 100mg daily as an alternative for participants with hypersensitivity to co-trimoxazole.
Duration: 12 months. Route: PO Receives: Drug: trimethoprim-sulfamethoxazole (co-trimoxazole) |
| ARM B: Stop immunoglobulin (without prophylactic antibiotics) | Experimental | Participants will be prescribed amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750 mg, to keep at home for initial use if symptoms of infection develop, with immediate review by their treating clinical team, or nearest emergency department or medical practitioner with phone contact to treating team if most practical.
Nb: clindamycin 600 mg is permitted as an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin.
Duration: 12 months. Route: PO Receives: Drug: amoxycillin/clavulanic acid and ciprofloxacin |
| ARM C: Continue immunoglobulin | Active comparator | Participants will continue treatment with their current Ig replacement schedule. Participants will receive either Intravenous Ig (IVIg) or Subcutaneous Ig (SCIg)
* IVIg: Participants will be treated in accordance with the Criteria for Clinical Use of Immunoglobulin in Australia. Monthly (every 4 weeks ± 1 week) dose of 0.4g/kg, modified to achieve an Immunoglobulin G (IgG) trough level of at least lower limit of age-specific serum IgG reference range. In the first month of therapy, if IgG <4g/L then an additional (loading) dose of 0.4g/kg may be given at the clinician's discretion.
* SCIg: Subcutaneous immunoglobulin weekly may be used in patients who meet local criteria for home based self-administration in centres with established SCIg programs. A loading IVIg dose may be given in the first month if required. Thereafter, dosing at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range.
Duration: 12 months. Receives: Drug: Immunoglobulins |
What is being measured
The primary outcome is the main question the study is designed to answer.
Event-free survival (EFS), defined as time from randomisation until occurrence of a Grade 3 or higher infection (as defined by CTCAE Version 5), or death from any cause.
Measured: 12 months following randomisation
Secondary outcomes (18)
Proportion of patients who develop at least 1 Grade 3 or higher infection(s) from randomisation to 12 months.
Measured: 12 months following randomisation
Proportion of patients with one or more clinically documented infections (symptoms/signs of infection requiring antimicrobial treatment) to 12 months.
Measured: 12 months following randomisation
Number of clinically documented infections (symptoms/signs of infection requiring antimicrobial treatment) to 12 months. Data collected from medical records will inform this outcome measure.
Measured: 12 months following randomisation
Proportion of patients with one or more microbiologically documented bacterial infections.
Measured: 12 months following randomisation
Number of microbiologically documented bacterial infections.
Measured: 12 months following randomisation
Time free from hospitalisation and antimicrobials with therapeutic intent.
Measured: 12 months following randomisation
Proportion of patients with one or more treatment-related adverse events
Measured: 12 months following randomisation
Number of treatment-related adverse events.
Measured: 12 months following randomisation
Proportion of patients with fluoroquinolone resistant organisms, co-trimoxazole resistant organisms, extended spectrum beta lactamases or multidrug resistant organisms isolated.
Measured: 12 months following randomisation
Number of infections with fluoroquinolone resistant organisms, co-trimoxazole resistant organisms, extended spectrum beta lactamases or multidrug resistant organisms isolated.
Measured: 12 months following randomisation
Quality of Life (QoL) measured at randomisation then 3, 6, 9 and 12 months
QoL will be assessed using the EORTC QLQ-C30 questionnaire.
Measured: Randomisation and 3, 6, 9 and 12 months following randomisation.
Quality of Life (QoL) measured at randomisation then 3, 6, 9 and 12 months
QoL will be assessed using the Functional Assessment of Cancer Therapy - Neutropenia (FACT-N) questionnaire.
Measured: Randomisation and 3, 6, 9 and 12 months following randomisation.
Quality of Life (QoL) measured at randomisation then 3, 6, 9 and 12 months
QoL will be assessed using the EQ-5D-5L questionnaire.
Measured: Randomisation and 3, 6, 9 and 12 months following randomisation.
Costs associated with allocated treatment arm and infections during study
Costs associated with each treatment arm with be aggregated into Australian dollars. Aggregate costs will be calculated based on the following data sources: medical records, infection-related hospitalisations (using unit costs based on unlinked data from the Victorian Admitted Episodes Dataset, Victorian Emergency Minimum Dataset and the Victorian Cost Data Collection), Medicare Benefits Scheme (MBS), Pharmaceutical Benefits Scheme (PBS) and Australian Immunisation Registry (AIR) data.
Measured: 12 months following randomisation
Cost effectiveness of the allocated treatment arm
Differences in costs and Quality Adjusted Life Years (QALYs) for each of the treatment arms will be aggregated into a cost effectiveness ratio. The following data sources will be used to calculate this outcome measure: the EORTC QLQ-C30 questionnaire will be used to calculate QALYS. Costs will be calculated based on the following data sources: medical records, infection-related hospitalisations (using unit costs based on unlinked data from the Victorian Admitted Episodes Dataset, Victorian Emergency Minimum Dataset and the Victorian Cost Data Collection), Medicare Benefits Scheme (MBS), Pharmaceutical Benefits Scheme (PBS) and Australian Immunisation Registry (AIR) data.
Measured: 12 months following randomisation
Trough IgG level at 3, 6, 9 and 12 months from baseline.
Measured: 3, 6, 9 and 12 months from baseline
Proportion of patients in immunoglobulin cessation treatment arms who restart Ig over 12 months.
Measured: 12 months following randomisation
Covid anti-spike protein levels at baseline, 3, 6, 9, and 12 months.
Measured: 3, 6, 9 and 12 months following baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jan 2023
- Study start30 Nov 2022
- Primary completionApr 2027 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Haematological MalignancyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Monash University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Erica Wood, Monash University
- Investigators
- Prof Erica Wood, Principal investigator, Monash UniversityProf Zoe McQuilten, Principal investigator, Monash University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05678621
- Sponsor's protocol ID
- TRU-RLS-21
- Acronym
- RATIONALISE
- Status last verified
- Apr 2024
- First submitted
- 11 Feb 2022
- Last updated
- 19 Apr 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be publicly available. Data will only be presented as a whole, no individual data will be published or presented.
Study at a glance
From the registry record, last updated by the sponsor on 19 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised Controlled Trial of Continuing Immunoglobulin Therapy, or Stopping With or Without Prophylactic Antibiotics, on Infection Rate in Patients With Acquired Hypogammaglobulinemia Secondary to Haematological Malignancies.
- ClinicalTrials.gov ID
- NCT05678621
- Acronym / sponsor ID
- RATIONALISE / TRU-RLS-21
- Conditions
- Haematological Malignancy, Hypogammaglobulinemia
- Keywords
- Myeloma, Lymphoma, Leukaemia, Blood cancer, Malignancy, Infection, Antibiotic, Anti-infective agent
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Monash UniversityUniversity, hospital or other
- Study start
- 30 Nov 2022 (actual)
- Primary completion
- Apr 2027 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 10 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to find out if patients with blood cancers receiving immunoglobulin (Ig) for the purpose of preventing infections can safety stop immunoglobulin after six months of therapy, and take oral antibiotics instead to prevent serious infections.
Patients may be eligible to join this study if they are aged 18 years or above, have an acquired hypogammaglobulinaemia secondary to a haematological malignancy, and have been receiving intravenous or subcutaneous Ig for longer than 6 consecutive months.
Participants will be randomised (allocated by chance) to one of three treatment groups, as follows:
- Stop immunoglobulin (IVIg or SCIg) and be given oral antibiotics to take every day (ARM A)
- Stop immunoglobulin (IVIg or SCIg) and be given oral antibiotics to keep at home to use as soon as symptoms of an infection develop (ARM B)
- Continue receiving immunoglobulin (IVIg or SCIg) - this is the usual care group (ARM C)
The duration of each treatment is for 12 months from study entry.
Participants will be asked to attend a screening/baseline visit so that their treating clinician can assess their eligibility for the trial and collect baseline data. If eligible for the trial, participants will then be randomly allocated to one of the three treatment groups.
Once randomised, active participation in the study will last for 13 months. During this period, participants will be asked to return to the hospital for a study visit every 3 months, with monthly telephone visits to check-in on your progress between each in-person visit. Participants will also be asked to complete a study diary, recording treatment compliance and signs/symptoms of infection experienced throughout the study period.
Types of assessments and data collected will include: Medical history, demographics, physical examination, blood tests, stool sample, quality of life questionnaires, information about your general health, hospitalisations, medications and procedures. In order to assess and compare the cost-effectiveness of the treatment groups, the study team will also request authorisation from participants to access their Medicare Benefits Schedule (MBS), Pharmaceutical Benefits Scheme (PBS), and Australian Immunisation Register (AIR) data.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| ARM A: Stop immunoglobulin (Ig) and commence prophylactic oral antibiotics | Experimental | Drug: trimethoprim-sulfamethoxazole (co-trimoxazole)Once daily trimethoprim-sulfamethoxazole (co-trimoxazole) 160mg/800mg. Nb: Doxycycline 100mg daily as an alternative for participants with hypersensitivity to co-trimoxazole. Duration: 12 months. Route: PO |
| ARM B: Stop immunoglobulin (without prophylactic antibiotics) | Experimental | Drug: amoxycillin/clavulanic acid and ciprofloxacinParticipants will be prescribed amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750 mg, to keep at home for initial use if symptoms of infection develop, with immediate review by their treating clinical team, or nearest emergency department or medical practitioner with phone contact to treating team if most practical. Nb: clindamycin 600 mg is permitted as an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin. Duration: 12 months. Route: PO |
| ARM C: Continue immunoglobulin | Active comparator | Drug: ImmunoglobulinsParticipants will continue treatment with their current Ig replacement schedule. Participants will receive either Intravenous Ig (IVIg) or Subcutaneous Ig (SCIg) * IVIg: Participants will be treated in accordance with the Criteria for Clinical Use of Immunoglobulin in Australia. Monthly (every 4 weeks ± 1 week) dose of 0.4g/kg, modified to achieve an Immunoglobulin G (IgG) trough level of at least lower limit of age-specific serum IgG reference range. In the first month of therapy, if IgG <4g/L then an additional (loading) dose of 0.4g/kg may be given at the clinician's discretion. * SCIg: Subcutaneous immunoglobulin weekly may be used in patients who meet local criteria for home based self-administration in centres with established SCIg programs. A loading IVIg dose may be given in the first month if required. Thereafter, dosing at 100mg/kg/week, modified to achieve an IgG steady state level of at least the lower limit of the serum reference range. Duration: 12 months. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Aged greater than or equal to 18 years of age
- Diagnosis of chronic lymphocytic leukaemia (CLL), multiple myeloma (MM) or non-Hodgkin lymphoma (NHL).
- Patients must be receiving Ig (IV or subcutaneous - SCIg) replacement for prevention of bacterial infections due to hypogammaglobulinaemia for longer than 6 consecutive months.
- Patient is eligible for trial of Ig cessation in the opinion of the treating clinician and local investigator.
- Life expectancy greater than 12 months.
Key exclusion criteria (10 listed)
- Prior or planned allogeneic haematopoietic stem cell transplantation.
- Major infection (Grade 3 or higher) in preceding 3 months, and/or current active infection requiring antimicrobial treatment.
- Already receiving daily antibiotic prophylaxis for the purpose of preventing bacterial infection (Note: patients may receive antiviral, antifungal and Pneumocystis jirovecii pneumonia (PJP) prophylaxis).
- Intolerance of all trial antibiotic options in either arm A or arm B.
- Communication, compliance or logistical issues that are likely to limit patient's ability to take prophylactic or emergency antibiotics, or to obtain urgent medical attention for symptoms of infection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| trimethoprim-sulfamethoxazole (co-trimoxazole)Doxycycline is an alternative for participants with hypersensitivity to co-trimoxazole. | Drug | ARM A: Stop immunoglobulin (Ig) and commence prophylactic oral antibiotics |
| amoxycillin/clavulanic acid and ciprofloxacinclindamycin is an alternative to amoxycillin/clavulanic acid for participants with hypersensitivity to penicillin. | Drug | ARM B: Stop immunoglobulin (without prophylactic antibiotics) |
| ImmunoglobulinsIntravenous monthly immunoglobulin or subcutaneous weekly immunoglobulin | Drug | ARM C: Continue immunoglobulin |
Primary outcome
Event-free survival (EFS), defined as time from randomisation until occurrence of a Grade 3 or higher infection (as defined by CTCAE Version 5), or death from any cause.
Time frame: 12 months following randomisation
18 secondary outcomes
Proportion of patients who develop at least 1 Grade 3 or higher infection(s) from randomisation to 12 months.
Time frame: 12 months following randomisation
Proportion of patients with one or more clinically documented infections (symptoms/signs of infection requiring antimicrobial treatment) to 12 months.
Time frame: 12 months following randomisation
Number of clinically documented infections (symptoms/signs of infection requiring antimicrobial treatment) to 12 months. Data collected from medical records will inform this outcome measure.
Time frame: 12 months following randomisation
Proportion of patients with one or more microbiologically documented bacterial infections.
Time frame: 12 months following randomisation
Number of microbiologically documented bacterial infections.
Time frame: 12 months following randomisation
Time free from hospitalisation and antimicrobials with therapeutic intent.
Time frame: 12 months following randomisation
Proportion of patients with one or more treatment-related adverse events
Time frame: 12 months following randomisation
Number of treatment-related adverse events.
Time frame: 12 months following randomisation
Proportion of patients with fluoroquinolone resistant organisms, co-trimoxazole resistant organisms, extended spectrum beta lactamases or multidrug resistant organisms isolated.
Time frame: 12 months following randomisation
Number of infections with fluoroquinolone resistant organisms, co-trimoxazole resistant organisms, extended spectrum beta lactamases or multidrug resistant organisms isolated.
Time frame: 12 months following randomisation
Quality of Life (QoL) measured at randomisation then 3, 6, 9 and 12 months
Time frame: Randomisation and 3, 6, 9 and 12 months following randomisation.
Quality of Life (QoL) measured at randomisation then 3, 6, 9 and 12 months
Time frame: Randomisation and 3, 6, 9 and 12 months following randomisation.
Quality of Life (QoL) measured at randomisation then 3, 6, 9 and 12 months
Time frame: Randomisation and 3, 6, 9 and 12 months following randomisation.
Costs associated with allocated treatment arm and infections during study
Time frame: 12 months following randomisation
Cost effectiveness of the allocated treatment arm
Time frame: 12 months following randomisation
Trough IgG level at 3, 6, 9 and 12 months from baseline.
Time frame: 3, 6, 9 and 12 months from baseline
Proportion of patients in immunoglobulin cessation treatment arms who restart Ig over 12 months.
Time frame: 12 months following randomisation
Covid anti-spike protein levels at baseline, 3, 6, 9, and 12 months.
Time frame: 3, 6, 9 and 12 months following baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Apr 2024.
- Individual participant dataSharing planned: No. Individual participant data will not be publicly available. Data will only be presented as a whole, no individual data will be published or presented.
Related trials for Haematological Malignancy
Not yet recruitingPhase 4
MACE and BTK Inhibitors
Hematologic Cancer, MACE
RecruitingEarly Phase 1
HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
Hematologic Malignancy
Recruiting
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Solid Tumor, Adult, Solid Tumor, Childhood
RecruitingObservational study
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Leukemia, Lymphoma
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Prof Erica Wood principal investigator
Monash University
Prof Zoe McQuilten principal investigator
Monash University
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin and Immunoglobulins in people with Haematological Malignancy and Hypogammaglobulinemia, run by Monash University at 7 sites in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Prof Zoe McQuilten (+61 3 9903 0379, zoe.mcquilten@monash.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Event-free survival (EFS), defined as time from randomisation until occurrence of a Grade 3 or higher infection (as defined by CTCAE Version 5), or death from any cause. (time frame: 12 months following randomisation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2024.